ofloxacin has been researched along with Fever of Unknown Origin in 7 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Fever of Unknown Origin: Fever in which the etiology cannot be ascertained.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia." | 9.11 | Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. ( Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T, 2004) |
| "We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resolution of neutropenia." | 9.11 | Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. ( Allione, B; Amadori, S; Bucaneve, G; Buelli, M; Cantaffa, R; Cilloni, D; D'Antonio, D; Del Favero, A; Deliliers, GL; Dionisi, MS; Fabbiano, F; Foà, R; Lauria, F; Martinelli, G; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Specchia, G; Zuffa, E, 2005) |
| " One hundred forty-eight cases received levofloxacin and 137 received amikacin, both in combination with ceftazidime." | 5.38 | Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. ( Bompolaki, I; Bozionelou, V; Falagas, ME; Kalpadaki, C; Karageorgopoulos, DE; Koutsounaki, E; Mitsikostas, P; Samonis, G; Sgouros, J; Taktikou, V, 2012) |
| "5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia." | 5.11 | Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. ( Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T, 2004) |
| "We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resolution of neutropenia." | 5.11 | Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. ( Allione, B; Amadori, S; Bucaneve, G; Buelli, M; Cantaffa, R; Cilloni, D; D'Antonio, D; Del Favero, A; Deliliers, GL; Dionisi, MS; Fabbiano, F; Foà, R; Lauria, F; Martinelli, G; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Specchia, G; Zuffa, E, 2005) |
| " After an initial work-up for fever, patients were randomized to receive oral ofloxacin 400 mg immediately and twice daily thereafter in the hospital or as outpatients." | 5.08 | Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. ( Aziz, Z; Karim, M; Khan, MA; Khan, WA; Malik, IA, 1995) |
| " He had noticed high fever since one month ago, and had been treated with prednisolone with the diagnosis of fever of unknown origin in a hospital." | 3.69 | [A case report--typhoid fever complicated with liver and gallbladder abscess, treated for long-time as fever of unknown origin]. ( Fukuda, J; Irimajiri, S; Kawashima, I; Matsuoka, Y; Obana, M; Suzuki, A; Suzuki, H; Suzuki, T, 1997) |
| " One hundred forty-eight cases received levofloxacin and 137 received amikacin, both in combination with ceftazidime." | 1.38 | Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. ( Bompolaki, I; Bozionelou, V; Falagas, ME; Kalpadaki, C; Karageorgopoulos, DE; Koutsounaki, E; Mitsikostas, P; Samonis, G; Sgouros, J; Taktikou, V, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calleris, G | 1 |
| Marra, G | 1 |
| Corcione, S | 1 |
| Oderda, M | 1 |
| Cardellino, C | 1 |
| Audagnotto, S | 1 |
| Frea, B | 1 |
| De Rosa, FG | 1 |
| Gontero, P | 1 |
| Samonis, G | 1 |
| Koutsounaki, E | 1 |
| Karageorgopoulos, DE | 1 |
| Mitsikostas, P | 1 |
| Kalpadaki, C | 1 |
| Bozionelou, V | 1 |
| Bompolaki, I | 1 |
| Sgouros, J | 1 |
| Taktikou, V | 1 |
| Falagas, ME | 1 |
| Cornely, OA | 1 |
| Wicke, T | 1 |
| Seifert, H | 1 |
| Bethe, U | 1 |
| Schwonzen, M | 1 |
| Reichert, D | 1 |
| Ullmann, AJ | 1 |
| Karthaus, M | 1 |
| Breuer, K | 1 |
| Salzberger, B | 1 |
| Diehl, V | 1 |
| Fätkenheuer, G | 1 |
| Bucaneve, G | 1 |
| Micozzi, A | 1 |
| Menichetti, F | 1 |
| Martino, P | 1 |
| Dionisi, MS | 1 |
| Martinelli, G | 1 |
| Allione, B | 1 |
| D'Antonio, D | 1 |
| Buelli, M | 1 |
| Nosari, AM | 1 |
| Cilloni, D | 1 |
| Zuffa, E | 1 |
| Cantaffa, R | 1 |
| Specchia, G | 1 |
| Amadori, S | 1 |
| Fabbiano, F | 1 |
| Deliliers, GL | 1 |
| Lauria, F | 1 |
| Foà, R | 1 |
| Del Favero, A | 1 |
| Baden, LR | 1 |
| Malik, IA | 1 |
| Khan, WA | 1 |
| Karim, M | 1 |
| Aziz, Z | 1 |
| Khan, MA | 1 |
| Kawashima, I | 1 |
| Suzuki, T | 1 |
| Suzuki, A | 1 |
| Obana, M | 1 |
| Suzuki, H | 1 |
| Matsuoka, Y | 1 |
| Irimajiri, S | 1 |
| Fukuda, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia[NCT03023384] | 547 participants (Anticipated) | Observational [Patient Registry] | 2016-12-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for ofloxacin and Fever of Unknown Origin
| Article | Year |
|---|---|
Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bacterial Infections; Disease Susceptibili | 2004 |
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacte | 2005 |
Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial.
Topics: Adult; Aged; Ambulatory Care; Feasibility Studies; Female; Fever; Fever of Unknown Origin; Humans; M | 1995 |
4 other studies available for ofloxacin and Fever of Unknown Origin
| Article | Year |
|---|---|
Miliary pulmonary infection after BCG intravesical instillation: a rare, misdiagnosed and mistreated complication.
Topics: Aged; Antitubercular Agents; BCG Vaccine; Bronchoalveolar Lavage Fluid; Carcinoma, Transitional Cell | 2017 |
Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Fever of Unkn | 2012 |
Prophylactic antimicrobial agents and the importance of fitness.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; Drug Res | 2005 |
[A case report--typhoid fever complicated with liver and gallbladder abscess, treated for long-time as fever of unknown origin].
Topics: Abscess; Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Cholecystectomy; Diagnostic Errors; | 1997 |